单克隆抗体在COVID-19管理中的应用综述

Umayal Adaikkalavan, Jeeja Mathummal Cherumanalil, Salwa Pannikkottuthodi, Hasna Poovancheri
{"title":"单克隆抗体在COVID-19管理中的应用综述","authors":"Umayal Adaikkalavan, Jeeja Mathummal Cherumanalil, Salwa Pannikkottuthodi, Hasna Poovancheri","doi":"10.18203/2319-2003.ijbcp20213645","DOIUrl":null,"url":null,"abstract":"Coronavirus disease 2019 (COVID-19) was declared as pandemic on March 11th 2020 by the world health organization (WHO). Vaccination is for preventing COVID-19 morbidity but when people are infected, treatment is required and even after one and half years the effective cure is yet to be discovered. In this context monoclonal antibodies (mAbs) are promising innovative therapeutic agents in controlling COVID-19 infection. Researchers have found more than 50 mAbs against COVID-19 and they are at different stages of development.  Scientists are pacing the research on mAbs. mAbs are innovative therapeutic agents in this context a scoping narrative review was done. At present we have evidences from numerous randomized controlled trials (RCT) on mAbs in effective control of respiratory and coagulation related complications due to COVID-19 infection. Many have got emergency use approval and few of which were withdrawn due to absence of enough evidences or adverse reactions. Examples are bamlanivimab, etesevimab, casirivimab and imdevimab. Other than these many investigational (mAbs) are under scrutiny. With the current evidences the article will give an insight to new and repurposed mAbs which are still under investigation in the management of COVID-19 infections.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"614 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Monoclonal antibodies in COVID-19 management: a scoping review\",\"authors\":\"Umayal Adaikkalavan, Jeeja Mathummal Cherumanalil, Salwa Pannikkottuthodi, Hasna Poovancheri\",\"doi\":\"10.18203/2319-2003.ijbcp20213645\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus disease 2019 (COVID-19) was declared as pandemic on March 11th 2020 by the world health organization (WHO). Vaccination is for preventing COVID-19 morbidity but when people are infected, treatment is required and even after one and half years the effective cure is yet to be discovered. In this context monoclonal antibodies (mAbs) are promising innovative therapeutic agents in controlling COVID-19 infection. Researchers have found more than 50 mAbs against COVID-19 and they are at different stages of development.  Scientists are pacing the research on mAbs. mAbs are innovative therapeutic agents in this context a scoping narrative review was done. At present we have evidences from numerous randomized controlled trials (RCT) on mAbs in effective control of respiratory and coagulation related complications due to COVID-19 infection. Many have got emergency use approval and few of which were withdrawn due to absence of enough evidences or adverse reactions. Examples are bamlanivimab, etesevimab, casirivimab and imdevimab. Other than these many investigational (mAbs) are under scrutiny. With the current evidences the article will give an insight to new and repurposed mAbs which are still under investigation in the management of COVID-19 infections.\",\"PeriodicalId\":13901,\"journal\":{\"name\":\"International Journal of Basic & Clinical Pharmacology\",\"volume\":\"614 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Basic & Clinical Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18203/2319-2003.ijbcp20213645\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Basic & Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/2319-2003.ijbcp20213645","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

2020年3月11日,世界卫生组织宣布2019冠状病毒病(COVID-19)为大流行。疫苗接种是为了预防COVID-19发病率,但当人们被感染时,需要进行治疗,甚至在一年半后仍未发现有效的治疗方法。在这种情况下,单克隆抗体(mab)是控制COVID-19感染的有希望的创新治疗药物。研究人员已经发现了50多种针对COVID-19的单克隆抗体,它们处于不同的开发阶段。科学家们正在对单克隆抗体进行研究。单克隆抗体是一种创新的治疗药物,在此背景下进行了范围叙述综述。目前,我们从大量随机对照试验(RCT)中获得了单克隆抗体有效控制COVID-19感染引起的呼吸和凝血相关并发症的证据。许多药物获得紧急使用批准,少数因证据不足或不良反应而被撤回。例如bamlanivimab, etesevimab, casirivimab和imdevimab。除此之外,许多研究性(单克隆抗体)正在接受审查。根据目前的证据,本文将深入了解在COVID-19感染管理中仍在研究中的新型和重新用途的单克隆抗体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Monoclonal antibodies in COVID-19 management: a scoping review
Coronavirus disease 2019 (COVID-19) was declared as pandemic on March 11th 2020 by the world health organization (WHO). Vaccination is for preventing COVID-19 morbidity but when people are infected, treatment is required and even after one and half years the effective cure is yet to be discovered. In this context monoclonal antibodies (mAbs) are promising innovative therapeutic agents in controlling COVID-19 infection. Researchers have found more than 50 mAbs against COVID-19 and they are at different stages of development.  Scientists are pacing the research on mAbs. mAbs are innovative therapeutic agents in this context a scoping narrative review was done. At present we have evidences from numerous randomized controlled trials (RCT) on mAbs in effective control of respiratory and coagulation related complications due to COVID-19 infection. Many have got emergency use approval and few of which were withdrawn due to absence of enough evidences or adverse reactions. Examples are bamlanivimab, etesevimab, casirivimab and imdevimab. Other than these many investigational (mAbs) are under scrutiny. With the current evidences the article will give an insight to new and repurposed mAbs which are still under investigation in the management of COVID-19 infections.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Current status of calcitonin gene-related peptide-based therapies in migraine: a scoping review Efficacy of current treatments against hepatitis C virus Adverse drug reactions to first line anti-tuberculosis drugs in newly diagnosed tuberculosis patients Comparing the effect of statins on hepatic fibrosis induced by carbon tetrachloride in Wistar rats Prescription audit of antihypertensive drugs used in stroke patients in a tertiary care teaching hospital
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1